Sai Parenterals
- P/E
- 79.75
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 5.28%
- Debt to Equity
- 0.96
- EPS (TTM)
- ₹6.00
- Book Value
- ₹46.57
- Market Cap
- —
- P/E (TTM)
- 79.75
- P/B
- 10.27
- ROE
- 4.88%
- Dividend Yield
- 0.00%
- EBITDA
- ₹47.20 Cr
- 52W High
- ₹706.00
- 52W Low
- ₹400.00
- Day Range
- ₹460.20 – ₹480.40
- Volume
- 64,640
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Sai Parenterals (this company) | ₹478.50 | 79.75 | ₹2,072 Cr | 10.27 | 0.00% | 4.88% | 5.28% | ₹681 Cr | ₹25 Cr |
| Median 8 companies | ₹1,587.70 | 58.71 | ₹1,25,337 Cr | 7.29 | 0.44% | 16.25% | 16.65% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Key Insights
Strengths
1- Debtor days have improved from 253 to 173 days.
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of 8.64% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 173 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 9 | 9 | 1 |
| Oscillators | Neutral | 1 | 7 | 1 |
| Moving Averages | Strong Bearish | 8 | 2 | 0 |
Oscillators
Neutral
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 45.99
- Neutral
- MACD (12,26,9)
- −7.19
- Bullish
- SMA (50)
- 504.62
- Bearish
- SMA (200)
- —
- Neutral
As of
Growth Rate
From the financial statements below. 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 3Y | +57.78% |
|---|---|
| 1Y | +133.74% |
Net profit
| 3Y | +51.83% |
|---|---|
| 1Y | 0.00% |
Operating cash flow
| 3Y | Turned positive |
|---|---|
| 1Y | +181.82% |
Operating margin· change in pp
| 3Y | −9.35 pp |
|---|---|
| 1Y | −13.69 pp |
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2023 | ₹97.00 Cr |
|---|---|
| Mar 2024 | ₹154 Cr |
| Mar 2025 | ₹163 Cr |
| Mar 2026 | ₹381 Cr |
Net profit by year
| Mar 2023 | ₹4.00 Cr |
|---|---|
| Mar 2024 | ₹8.00 Cr |
| Mar 2025 | ₹14.00 Cr |
| Mar 2026 | ₹14.00 Cr |
AI Analysis — Bull vs Bear
Sai Parenterals Ltd is a small-cap healthcare company (market cap ~₹2,756 Cr) that has delivered explosive TTM sales growth of 134% (revenue scaling from ~₹97 Cr in FY23 to ~₹381 Cr in FY26) but trades at a steep PE of 191.9x with compressed profitability — net profit of ₹14.26 Cr on ₹381 Cr revenue (OPM ~10%) and ROE declining to ~5% in the last year.
- TTM revenue growth of 134% signals rapid business scale-up, with sales rising from ₹97 Cr (FY23) to ₹381 Cr (FY26)
- 3-year compounded sales CAGR of 58% demonstrates sustained top-line momentum, not a one-off spike
- 3-year compounded profit CAGR of 48% shows earnings have scaled alongside revenue over a multi-year horizon
- Debtor days improved from 253 to 173 days, indicating better working capital management and faster collections
- Revenue of ₹381 Cr in FY26 vs ₹97 Cr in FY23 represents nearly 4x scale in three years, rare in the parenteral/injectable space
- Operating profit grew from ₹17.62 Cr (FY23) to ₹38.70 Cr (FY26), more than doubling absolute EBITDA
- Negative effective tax rate of -19.54% in FY26 boosted reported net profit, potentially reflecting deferred tax assets or incentives that may continue near-term
- ROE declined from 9% (3-year average) to just 5% last year, indicating capital is not generating adequate returns despite revenue growth
- Low interest coverage ratio flagged as a risk — interest expense of ₹18.44 Cr against PBT of ₹11.93 Cr in FY26 means interest exceeds pre-tax profit
- Operating profit margin compressed to ~10% in FY26 from ~18% in FY23, suggesting growth is coming at the cost of profitability
- Debtor days still elevated at 173 days, tying up significant working capital relative to revenue of ₹381 Cr
- Zero dividend yield indicates no cash return to shareholders despite the ₹2,756 Cr market cap valuation
- TTM profit growth of -1% despite 134% sales growth shows severe margin dilution and cost pressures
- EPS declined from ₹6.12 (FY23) to ₹3.23 (FY26) despite revenue nearly quadrupling, reflecting equity dilution or margin compression
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Sai Parenterals is in a bullish phase driven by its subsidiary Noumed Pharmaceuticals securing a large AUD 202 Mn OTC supply deal in Australia, demonstrating international expansion traction. The board's authorization to pursue organic and inorganic growth adds to the positive momentum. No material headwinds are visible in recent news. The trend is improving with international revenue diversification strengthening the outlook.
- Subsidiary wins AUD 202Mn order Jul 1
Subsidiary Noumed Pharmaceuticals signed an OTC supply deal worth AUD 202 Mn with an Australian pharmacy network, providing significant revenue visibility.
- Board authorizes growth opportunities Jul 6
The board authorized the Managing Director to identify organic and inorganic growth opportunities, signaling intent to scale beyond current operations.
- Auditor appointments for FY27 Jul 6
Board appointed M/s. Aakanksha Dubey & Co. as Secretarial Auditors for five years (2026-27 to 2030-31), along with internal and cost auditors for FY 2026-27.
- Analyst meet hosted by Axis Capital Jun 30
Virtual analyst meeting held on July 2, 2026, hosted by Axis Capital, covering only publicly available information.
Quarterly Results
₹ Cr| Particulars | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Sales | 33.39 | 96.15 | 198 | 179 | 195 |
| Expenses | 28.65 | 99.71 | 172 | 155 | 155 |
| Operating Profit | 4.74 | −3.56 | 26.1 | 23.52 | 40.24 |
| OPM % | 14.2% | −3.7% | 13.19% | 13.16% | 20.64% |
| Other Income | 1.17 | 3.13 | 2.88 | 3.74 | 3.72 |
| Interest | 2.46 | 5.41 | 8.4 | 9.36 | 8.98 |
| Depreciation | 1.45 | 5.79 | 8.18 | 8.11 | 25.09 |
| PBT | 2 | −11.62 | 12.4 | 9.79 | 9.89 |
| Tax % | 29.5% | −42.65% | −6.13% | 19% | −6.27% |
| Net Profit | 1.42 | −6.66 | 13.16 | 7.92 | 10.51 |
| EPS (₹) | 0.52 | −1.8 | 2.98 | 1.79 | — |
Sep 2026: from the results filed on 1 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 97 | 154 | 163 | 381 |
| Expenses | 78 | 122 | 124 | 342 |
| Operating Profit | 19 | 32 | 39 | 39 |
| OPM % | 19% | 21% | 24% | 10% |
| Other Income | 0 | 1 | 1 | 9 |
| Interest | 6 | 11 | 12 | 18.44 |
| Depreciation | 6 | 9 | 8 | 17 |
| PBT | 7 | 13 | 20 | 12 |
| Tax % | 40% | 33% | 28% | −20% |
| Net Profit | 4 | 8 | 14 | 14 |
| EPS (₹) | 6.13 | 6.36 | 5.43 | 3.23 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 61 | 80 | 469 |
| Borrowings | 69 | 119 | 94 | 469 |
| Other Liabilities | 34 | 75 | 85 | 465 |
| Total Liabilities | 134 | 268 | 272 | 1,424 |
| Fixed Assets | 44 | 70 | 53 | 364 |
| CWIP | 2 | 0 | 0 | 212 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 88 | 198 | 219 | 848 |
| Total Assets | 134 | 268 | 272 | 1,424 |
Cash Flow
₹ Cr| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | −13 | −30 | 33 | 93 |
| Investing | −19 | −46 | 0 | −274 |
| Financing | 24 | 79 | −36 | 596 |
| Net Cash Flow | −8 | 2 | −2 | 415 |
| Free Cash Flow | −30 | −72 | 41 | −184 |
| CFO/OP | −54 | −94 | 86 | 253 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 231 | 302 | 283 | 173 |
| Inventory Days | 83 | 143 | 199 | 259 |
| Days Payable | 140 | 203 | 225 | 224 |
| Cash Conversion Cycle | 174 | 242 | 256 | 208 |
| Working Capital Days | 19 | 72 | 79 | −161 |
| ROCE % | — | 16% | 17% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sai Parenterals insights
53 extracted metrics across FY23–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Concall · May 2026Transcript PPT
- General announcements 1 Nov 2026
Frequently Asked Questions about Sai Parenterals
What does Sai Parenterals Ltd do?
Where is Sai Parenterals Ltd (SAIPARENT) listed?
Which sector does Sai Parenterals Ltd belong to?
What is the PE ratio of Sai Parenterals Ltd?
What is the 52-week high and low of Sai Parenterals Ltd?
What is the Return on Equity (ROE) of Sai Parenterals Ltd?
Company Information
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SAIPARENT.md for Sai Parenterals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.